BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
November 29, 2012 at 08:30 AM EST
Atossa Genetics, Inc. to Present at the 5th Annual LD Micro Conference

SEATTLE, WA -- (Marketwire) -- 11/29/12 -- Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that Dr. Steven C. Quay, M.D., Ph.D., FCAP, chairman, CEO and president of Atossa Genetics, Inc., will present at the 5th Annual LD Micro Conference on Wednesday, December 5, 2012, at 10:00 AM Pacific Time, at the Luxe Sunset Bel Air Hotel in Los Angeles, California.

Dr. Quay's presentation will focus on the Company's novel approaches to breast cancer risk assessment and prevention, 2013 growth initiatives for its first year as a public company, and its unique investment thesis.

A link to the live audio webcast with slides of the presentation can be accessed on Atossa's website. After clicking on the webcast link, visitors will be directed to the proper conference's registration page. After completing the required fields and clicking "Register," visitors will then be brought to the dedicated webcast page. A replay of the webcast will be available for 90 days after the presentation and can be accessed at the same web address.

The LD Micro Conference is a two-day conference organized by LD Micro, a by-invitation only newsletter firm that provides micro-cap research for its clients. The LD Micro Conference focuses on undervalued micro-cap companies in a broad range of industries. A record 580 investors attended the 2011 event. Investors interested in attending the conference should call 408-457-1042 or e-mail Chris@ldmicro.com, or visit the conference website.

About Atossa Genetics, Inc.

Atossa Genetics, Inc., The Breast Health Company¬ô, is based in Seattle, Washington, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:

Atossa Genetics, Inc.
Steven C. Quay, M.D., Ph.D., FCAP
Chairman, President and CEO of Atossa Genetics and
Director of the National Reference Laboratory for Breast Health
800-351-3902 ext. 103
Email Contact

Matthew D. Haines (Investors and Media)
Managing Director
MBS Value Partners
212-710-9686
Email Contact

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here